A Phase 2 interventional study of PrEP Decision Aid and Generic Information in Sexual Risk Behavior for HIV-infection and Reproductive Health, sponsored by Yale University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Yale University · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in HIV Infections by Yale University — 2 open to participants now, 3 under way, none of them phase 3. HIV Infections · Yale University.
Among the 30 studies in HIV Infections by Yale University, this one is the 18th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 29th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →2 of the 30 studies in HIV Infections by Yale University are open now, in 2 countries. Recruiting first, the newest first:
Yale University · Sites in Uganda
Ages 18–45 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 60 across the 27 interventional studies, 80 across the 3 observational. Of the 26 that completed or were terminated, 5 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
2 of the studies in HIV Infections by Yale University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06684613Yale UniversityIntegrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health Clinics | 2027-03-01 |
| NCT05668780Yale UniversityBuprenorphine Integration Research and Community Health | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in HIV Infections by Yale University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study addresses the need for HIV prevention to be integrated into counseling visits at sexual and reproductive health clinics.
The purpose of this study is to expand and enhance a PrEP decision aid to include the full array of available formulation options and then integrate its delivery into sexual and reproductive health settings during counseling visits, where PrEP can be provided to all women who are interested. Rooted in health implementation frameworks, this study evaluates health and implementation determinants simultaneously along: 1) innovation characteristics; 2) clinical encounter; 3) recipients; and 4) context.
In Aim 1, patients (n=15-20), clinicians (n=10), and staff (n=10) at sexual and reproductive health clinics across Greater New Haven, CT will be engaged for semi-structured interviews to expand and enhance an existing PrEP decision aid to include all available formulations and optimize its integration into sexual and reproductive health clinics. Qualitative interviews will inform infrastructure development to support PrEP delivery in sexual and reproductive health clinics.
In Aim 2 (a hybrid Type 2 effectiveness-implementation study), patients will be randomized (n=50) to receive either the PrEP decision aid or generic PrEP information prior to a clinician visit. In follow-up interviews immediately post-visit, and at Months 3 and 6, primary outcomes are clinical efficacy (PrEP initiation) and implementation (using Proctor definitions for feasibility, acceptability, penetration, and adoption) that are important for future planned scale-up.
Patients (inclusion):
Patients (exclusion):
Sexual and Reproductive Health clinicians will be included if they provide sexual and reproductive health patient care at any of the participating sites. Clinic staff will be included if they work at any of the participating sites and have patient-facing or non-patient-facing roles .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the decision aid (active intervention arm), will interact with the enhanced PrEP decision aid in REDCap. This is an individualized, patient-facing decision aid that supports informed patient choice and is interactive. In contrast to shared decision aids that guide a clinical encounter, the participants uses the individualized decision aid prior to the clinical encounter to discretely assess HIV risk and build awareness before discussing with their clinician
Device: PrEP Decision Aid
Participants randomized to this arm will be asked to watch a CDC-produced video, "PrEP (Pre-Exposure Prophylaxis)" (available online free of charge through CDC website) that will serve as a time- and attention-based control.
Other: Generic Information
Patient-facing decision-aid on PrEP that will be enhanced to include various formulations of available PrEP. Can be integrated into sexual and reproductive health clinics as part of counseling.
Participants will be asked to watch a CDC-produced video, "PrEP (Pre-Exposure Prophylaxis" (available online free of charge through the CDC web site). The video will serve as a time- and attention- based control to the decision aid.
PrEP initiation (prescribing)
Whether PrEP was prescribed (yes/no) in the EHR within the 6-month time frame
Time frame: 6 months
Feasibility of implementing the enhanced PrEP decision aid in SRH settings, according to the Proctor taxonomy
Feasibility is defined as the extent to which the enhanced PrEP decision aid can be successfully used in SRH clinic settings (qualitative).
Time frame: 6 months
Acceptability of the enhanced PrEP decision aid within SRH settings, according to users (Proctor taxonomy)
Acceptability is defined as the user perception that the enhanced PrEP decision aid is acceptable in SRH settings.
Time frame: 6 months
Penetration (reach) of the enhanced decision aid within SRH clinics (Proctor taxonomy)
Penetration (reach) of the intervention, measured by recruitment rate (number of participants enrolled per month)
Time frame: 6 months
Penetration (reach) of the enhanced decision aid within SRH clinics (Proctor taxonomy)
Penetration (reach) of the intervention, measured by completion rate (percentage of participants completing 6-month interviews out of those enrolled)
Time frame: 6 months
Penetration (reach) of the enhanced decision aid within SRH clinics (Proctor taxonomy)
Penetration (reach) of the intervention, measured by reasons for not meeting inclusion criteria
Time frame: 6 months
Adoption of the enhanced PrEP decision aid within SRH settings, according to users (Proctor taxonomy)
Adoption of the enhanced decision aid into SRH clinics, assessed by whether PrEP was discussed during the visit (yes/no)
Time frame: 6 months
PrEP initiation (dispensing)
Whether PrEP was dispensed (yes/no) in the EHR within the 6-month time frame
Time frame: 6 months
PrEP initiation (first use)
Whether PrEP was started by the patient within the 6 months' time frame (yes/no)
Time frame: 6 months
PrEP adherence
Non-pharmacokinetic: (subjective) 3-item self-report with 30-day look-back
Time frame: 6 months
PrEP adherence
Non-pharmacokinetic: (objective) pharmacy refill data or injection dates for LAI.
Time frame: 6 months
PrEP adherence
Pharmacokinetic: (objective) urine tenofovir levels (units detected/ not detected)
Time frame: 6 months
PrEP persistence
Dates of completed PrEP encounters in EHR (i.e., clinic dates)
Time frame: 6 months
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 11 months after the start.
Of 64 non-industry phase 2 interventional studies under HIV Infections, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 74. This study's planned 11 months is below that.
Counting every sponsor, half of 98 studies reached it within 31 months; a quarter within 17 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.